NASDAQ: ANIPAni Pharmaceuticals Inc Stock
$69.21+0.01 (+0.01%)
Updated Apr 17, 2025
ANIP Price
$69.21
Fair Value Price
N/A
Market Cap
$1.51B
52 Week Low
$52.50
52 Week High
$70.48
P/E
-66.55x
P/B
3.73x
P/S
1.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$614.38M
Earnings
-$18.52M
Gross Margin
59.3%
Operating Margin
-0.75%
Profit Margin
-3.3%
Debt to Equity
2.12
Operating Cash Flow
$64M
Beta
0.86
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ANIP Overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANIP's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ANIP
Ranked#13 of 54
Ranked#13 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important ANIP news, forecast changes, insider trades & much more!
ANIP News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANIP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANIP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ANIP is poor value based on its book value relative to its share price (3.73x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.99x)
P/B vs Industry Valuation
ANIP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ANIP due diligence checks available for Premium users.
Valuation
ANIP fair value
Fair Value of ANIP stock based on Discounted Cash Flow (DCF)
Price
$69.21
Fair Value
-$55.94
Undervalued by
223.71%
ANIP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANIP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-66.55x
Industry
20.48x
Market
27.98x
ANIP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.73x
Industry
1.99x
ANIP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANIP's financial health
Profit margin
Revenue
$190.6M
Net Income
-$10.3M
Profit Margin
-5.6%
ANIP's Earnings (EBIT) of -$4.61M... subscribe to Premium to read more.
Interest Coverage Financials
ANIP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$855.2M
Debt to equity
2.12
ANIP's short-term assets ($527.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIP's long-term liabilities ($661.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ANIP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.9M
Investing
-$10.7M
Financing
-$4.9M
ANIP's operating cash flow ($64.02M)... subscribe to Premium to read more.
Debt Coverage Financials
ANIP vs Pharmaceutical Stocks
Ani Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.